ezetimibe has been researched along with Diabetes Mellitus, Type 1 in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Adamson, SS; Biddinger, SB; Bullock, K; Chahar, S; Clish, CB; Crooke, RM; de Ferranti, SD; Gearing, ME; Graham, MJ; Hagey, LR; Kidambi, S; Krawczyk, J; Levenson, AE; Ling, AV; Miao, J; Semova, I; Shin, DJ; Vicent, D; Williams, KA | 1 |
| Bramlage, P; Brandts, J; Brix, JM; Danne, T; Heyer, CHJ; Holl, RW; Müller-Wieland, D; Tittel, SR; Zimny, S | 1 |
| Sattar, N; Sillars, A | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; Pirags, V; Rosen, JB; Triscari, J; Vides, H | 1 |
| Ciriacks, K; Coly, G; Kidambi, S; Krishnaswami, S; Patel, SB | 1 |
| Fövényi, J; Gaál, Z; Gyimesi, A; Hídvégi, T; Hosszúfalusi, N; Jermendy, G; Nádas, J; Neuwirth, G; Oroszlán, T; Pánczél, P; Putz, Z; Vándorfi, G; Winkler, G; Wittmann, I | 1 |
| Bantly, A; Hamamdzic, D; Mohler, ER; Moore, J; Parmacek, M; Putt, M; Rader, DJ; Shi, Y; Wilensky, RL; Yoder, M; Zhang, L | 1 |
| Betteridge, DJ; Brudi, P; Farnier, M; Guyton, JR; Johnson-Levonas, AO; Leiter, LA; Lin, J; Shah, A | 1 |
| Martin, PY; Saudan, P | 1 |
| Almquist, T; Farndale, RW; Hjemdahl, P; Jacobson, SH; Lins, PE | 1 |
| Holland, RC; Lopez, D; Ness, GC | 1 |
| Berthold, J; Krone, W | 1 |
| Jehlicka, P; Mayer, O; Racek, J; Siala, K; Stožický, F; Trefil, L; Varvařovská, J | 1 |
1 review(s) available for ezetimibe and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Management of Lipid Abnormalities in Patients with Diabetes.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents | 2019 |
4 trial(s) available for ezetimibe and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Insulin Prevents Hypercholesterolemia by Suppressing 12α-Hydroxylated Bile Acids.
Topics: Animals; Bile Acids and Salts; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 1; Ezetimibe; Humans; Hypercholesterolemia; Hyperlipidemias; Insulin; Liver; Mice; Receptor, Insulin; Simvastatin; Steroid 12-alpha-Hydroxylase | 2022 |
Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Obesity; Peptide Fragments; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
Effects of lipid-lowering treatment on platelet reactivity and platelet-leukocyte aggregation in diabetic patients without and with chronic kidney disease: a randomized trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Blood Platelets; Cross-Over Studies; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Double-Blind Method; Ezetimibe; Female; Flow Cytometry; Follow-Up Studies; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Leukocytes; Lipids; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Prognosis; Risk Factors; Simvastatin; Young Adult | 2012 |
Asymmetric dimethylarginine and the effect of folate substitution in children with familial hypercholesterolemia and diabetes mellitus type 1.
Topics: Adolescent; Anticholesteremic Agents; Arginine; Azetidines; Biomarkers; Child; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Female; Folic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Male; Risk Factors; Ultrasonography; Vitamin B Complex | 2009 |
8 other study(ies) available for ezetimibe and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in type 1 diabetes and type 2 diabetes: Lipid goal attainment in a large German-Austrian diabetes registry.
Topics: Adult; Aged; Anticholesteremic Agents; Atherosclerosis; Austria; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dyslipidemias; Ezetimibe; Fibric Acids; Goals; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Proprotein Convertase 9; Registries | 2023 |
Effects of simvastatin and ezetimibe in lowering low-density lipoprotein cholesterol in subjects with type 1 and type 2 diabetes mellitus.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Body Mass Index; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Middle Aged; Prospective Studies; Simvastatin; Waist Circumference | 2015 |
[Effectiveness of cardiometabolic risk reduction in patients with type 1 diabetes mellitus].
Topics: Adult; Anticholesteremic Agents; Antihypertensive Agents; Azetidines; Blood Pressure; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Diabetes Mellitus, Type 1; Ezetimibe; Female; Glycated Hemoglobin; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Metabolic Syndrome; Middle Aged; Practice Guidelines as Topic; Risk Assessment; Risk Factors; Surveys and Questionnaires; Treatment Outcome; Triglycerides | 2008 |
Diabetes reduces bone marrow and circulating porcine endothelial progenitor cells, an effect ameliorated by atorvastatin and independent of cholesterol.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Animals; Antibiotics, Antineoplastic; Anticholesteremic Agents; Atorvastatin; Azetidines; Bone Marrow Cells; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Endothelial Cells; Ezetimibe; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Stem Cells; Swine; Vasodilation | 2009 |
Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome; Young Adult | 2011 |
[Nephrology].
Topics: Anticholesteremic Agents; Azathioprine; Azetidines; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Kidney Failure, Chronic; Lupus Nephritis; Mycophenolic Acid; Nephrology; Renal Dialysis; Secondary Prevention; Simvastatin; Treatment Outcome | 2012 |
Selective compensatory induction of hepatic HMG-CoA reductase in response to inhibition of cholesterol absorption.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol, Dietary; Diabetes Mellitus, Type 1; Enzyme Induction; Ezetimibe; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Liver; Male; Rats; Rats, Sprague-Dawley; Receptors, LDL; Thyroid Hormones; Thyroidectomy; Transcription, Genetic | 2006 |
[Type 1 diabetes: what are the alternatives for lowering cholesterol levels with statins?].
Topics: Anticholesteremic Agents; Azetidines; Diabetes Mellitus, Type 1; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Rhabdomyolysis | 2007 |